Relay Therapeutics, Inc. (RLAY)
| Market Cap | 2.32B +313.3% |
| Revenue (ttm) | 10.68M +39.0% |
| Net Income | -272.71M |
| EPS | -1.57 |
| Shares Out | 191.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,297,367 |
| Open | 12.23 |
| Previous Close | 12.20 |
| Day's Range | 11.63 - 12.57 |
| 52-Week Range | 2.75 - 17.32 |
| Beta | 1.75 |
| Analysts | Strong Buy |
| Price Target | 21.00 (+73.55%) |
| Earnings Date | May 5, 2026 |
About RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R... [Read more]
Financial Performance
In 2025, Relay Therapeutics's revenue was $15.36 million, an increase of 53.44% compared to the previous year's $10.01 million. Losses were -$276.48 million, -18.13% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price target is $21.0, which is an increase of 73.55% from the latest price.
News
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...
Relay Therapeutics price target raised to $25 from $19 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Relay Therapeutics (RLAY) to $25 from $19 and keeps a Buy rating on the shares. The firm says the Phase 1 zovegalisib…
Relay Therapeutics price target raised to $18 from $14 at Oppenheimer
Oppenheimer raised the firm’s price target on Relay Therapeutics (RLAY) to $18 from $14 and keeps an Outperform rating on the shares. The firm thought Relay’s zovegalisib triplet data check…
Relay Therapeutics price target raised to $21 from $17 at Wells Fargo
Wells Fargo raised the firm’s price target on Relay Therapeutics (RLAY) to $21 from $17 and keeps an Overweight rating on the shares. The firm believes the update for zovegalisib…
Relay Therapeutics price target raised to $22 from $13 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm’s price target on Relay Therapeutics (RLAY) to $22 from $13 and keeps a Buy rating on the shares. Relay Therapeutics reported early…
Relay Therapeutics price target raised to $19 from $17 at Citizens
Citizens analyst Silvan Tuerkcan raised the firm’s price target on Relay Therapeutics (RLAY) to $19 from $17 and keeps an Outperform rating on the shares. Relay’s triplet regimen has shown…
Relay Therapeutics Transcript: Study result
The zovegalisib/atirmociclib/fulvestrant triplet showed a 44% ORR and favorable tolerability in heavily pretreated metastatic breast cancer patients, supporting advancement to a phase III frontline trial targeting PI3Kα-mutated, endocrine-sensitive patients. Regulatory discussions and trial initiation are planned for early next year.
Relay Therapeutics’ combination for breast cancer shows efficacy and safetyPfizer
Relay Therapeutics (RLAY) announced plans to move zovegalisib + atirmociclib, Pfizer’s (PFE) investigational, potential first-in-class CDK4 inhibitor, into Phase 3 development for frontline patients w...
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-tre...
Relay Therapeutics initiated with a Hold at JonesResearch
JonesResearch analyst Boris Peaker initiated coverage of Relay Therapeutics (RLAY) with a Hold rating and $18 price target The firm views bullish on Relay’s pipeline and zovegalisib’s prospects. It ci...
Relay Therapeutics price target raised to $21 from $17 at Barclays
Barclays analyst Peter Lawson raised the firm’s price target on Relay Therapeutics (RLAY) to $21 from $17 and keeps an Overweight rating on the shares. The firm is positive on…
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...
Relay Therapeutics price target raised to $19 from $14 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Relay Therapeutics (RLAY) to $19 from $14 and keeps a Buy rating on the shares. The firm updated the company’s model post…
Relay Therapeutics price target raised to $17 from $15 at Citizens
Citizens raised the firm’s price target on Relay Therapeutics (RLAY) to $17 from $15 and keeps an Outperform rating on the shares. Relay Therapeutics reported updated 2L+ aBC data at…
Relay Therapeutics announces data from Phase 1/2 ReDiscover trial
Relay Therapeutics (RLAY) announced data from the Phase 1/2 ReDiscover trial of zovegalisib + fulvestrant at the recommended Phase 3 dose of 400mg twice daily taken with food in patients…
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast...
Relay Therapeutics price target raised to $22 from $15 at Guggenheim
Guggenheim analyst Brad Canino raised the firm’s price target on Relay Therapeutics (RLAY) to $22 from $15 and keeps a Buy rating on the shares. An updated analysis of Novartis’…
Relay Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
The focus is on advancing a mutant-selective PI3Kα inhibitor, zovegalisib, in metastatic breast cancer and vascular anomalies, with key data readouts expected this year and in 2026. Strong cash reserves support ongoing trials and research, with multiple catalysts anticipated.
Relay Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Key updates include imminent data releases for zovegalisib in breast cancer and vascular anomalies, with a focus on demonstrating differentiated efficacy and safety. Enrollment in pivotal trials is progressing, and the company is targeting large, underserved patient populations with potential for accelerated approval.
Relay Therapeutics reports Q4 EPS (32c), consensus (39c)
Reports Q4 revenue $7M, consensus $4.97M. “Our focus on disciplined execution to date has strengthened the foundation of Relay, aligning our organization to support long-term success. In 2026, Relay i...
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced i...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...